Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  TiGenix NV    TIG   BE0003864817

TIGENIX NV (TIG)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
04/19/2018 04/20/2018 04/23/2018 04/24/2018 04/25/2018 Date
1.758(c) 1.756(c) 1.746(c) 1.74(c) 1.758 Last
108 373 145 792 909 834 560 754 494 630 Volume
-0.11% -0.11% -0.57% -0.34% +1.03% Change
More quotes
Financials (EUR)
Sales 2018 25,4 M
EBIT 2018 -18,9 M
Net income 2018 -21,6 M
Debt 2018 21,0 M
Yield 2018 -
Sales 2019 4,95 M
EBIT 2019 -44,5 M
Net income 2019 -46,6 M
Debt 2019 77,0 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 21,2x
EV / Sales2019 120x
Capitalization 517 M
More Financials
Company
TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products.Its portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells.The company intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial... 
More about the company
Surperformance© ratings of TiGenix NV
Trading Rating : Investor Rating :
More Ratings
Latest news on TIGENIX NV
04/17TIGENIX : reports 2017 full year results
AQ
04/13TIGENIX : Transparency notification pursuant to Article 14 of the Law of May 2, ..
PU
04/13TIGENIX : Transparency notification pursuant to Article 14 of the Law of May 2,..
GL
04/13TIGENIX : reports 2017 full year results
AQ
04/13TIGENIX : Transparency notifications pursuant to Article 14 of the Law of May 2,..
AQ
04/12TIGENIX : reports 2017 full year results
GL
04/12TIGENIX NV : Annual results
CO
04/10TIGENIX : Transparency notifications pursuant to Article 14 of the Law of May 2,..
PU
04/10TIGENIX : Transparency notifications pursuant to Article 14 of the Law of May 2..
GL
04/04TIGENIX : EC approves Alofisel for complex perianal fistulae in Crohns disease
AQ
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07:09aTakeda Announces Voluntary and Conditional Public Takeover Bid for Outstandin.. 
04/14TiGenix: Transparency notification pursuant to Article 14 of the Law of May .. 
04/12TiGenix reports 2017 full year results  
04/12TiGenix : reports 2017 full year results  
04/11TiGenix: Transparency notifications pursuant to Article 14 of the Law of May.. 
More tweets
Qtime:56
News from SeekingAlpha
04/12Tigenix Sa reports FY results 
01/31BONE THERAPEUTICS : In (Re)Search For Money 
01/12Takeda's Offer On Tigenix - Good Deal Or Not? 
2017TIGENIX : This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come 
2017Tigenix Sa reports FY results 
Chart TIGENIX NV
Duration : Period :
TiGenix NV Technical Analysis Chart | TIG | BE0003864817 | 4-Traders
Technical analysis trends TIGENIX NV
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 1,62 €
Spread / Average Target -6,9%
EPS Revisions
Managers
NameTitle
Eduardo Bravo Fernández de Araoz Chief Executive Officer, Executive Director & MD
Jean Stéphenne Chairman
Claudia D'Augusta Chief Financial Officer & Compliance Officer
Wilfried Dalemans Chief Technical Officer
Marie Paule Richard Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
TIGENIX NV79.01%631
GILEAD SCIENCES2.88%96 094
VERTEX PHARMACEUTICALS5.53%40 153
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB21.82%12 797
BEIGENE LTD (ADR)73.75%8 998